Group 1 - The company, Haijia Medical (06078.HK), announced a share buyback on December 23, 2023, spending HKD 2.9993 million to repurchase 238,800 shares [1] - The buyback price per share ranged from HKD 12.50 to HKD 12.62 [1]

Group 1 - The company, Haijia Medical (06078), announced a share buyback plan, intending to repurchase 238,800 shares at a cost of HKD 2.9993 million [1] - The buyback is scheduled to take place on December 23, 2025 [1] - This move indicates the company's strategy to enhance shareholder value through share repurchase [1]

Group 1 - The company, Haijia Medical (06078), announced a share buyback plan [1] - The total amount allocated for the buyback is HKD 2.9993 million [1] - The company plans to repurchase 238,800 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 呈交日期： 2025年12月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06078 | 說明 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發 ...

Group 1 - The company, Haijia Medical (06078.HK), announced a share buyback on December 22, 2023, spending HKD 533,000 to repurchase 41,800 shares [1]

Group 1 - The company, Haijia Medical (06078), announced a share buyback of 41,800 shares at a cost of HKD 532,950 on December 22, 2025 [1]

Group 1 - The company, Haijia Medical (06078), announced a share buyback plan, spending HKD 532,950 to repurchase 41,800 shares on December 22, 2025 [1]

表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 海吉亞醫療控股有限公司 呈交日期： 2025年12月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06078 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Group 1 - The "Annual Outstanding Healthcare Enterprises" award recognizes companies in the Chinese healthcare industry that excel in innovation, technological leadership, market influence, social value, and sustainable development [4] - The award winners include Alibaba Health (00241.HK), Anxuyuan, Baize Medical (02609.HK), Gushengtang (02273.HK), Haijia Medical (06078.HK), Jinhua Medical Group (01110.HK), Kangchen Pharmaceutical (01681.HK), Ping An Good Doctor (01833.HK), Weitai Medical-B (02235.HK), and Xinwei Medical-B (06609.HK) [1] - The selection process involved quantitative data analysis and an expert review panel to determine the final results [4] Group 2 - The "Jin Ge Award" aims to create a reference for the investment community by highlighting the most valuable listed companies and unicorns in China [4] - The evaluation covers all listed companies and unicorns on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, American Stock Exchange, and NASDAQ [4]

Core Viewpoint - The company, Haijia Medical, announced a share buyback program due to its stock price not reflecting its intrinsic value or business prospects, committing to repurchase shares for at least RMB 300 million [1] Group 1: Share Buyback Announcement - On December 15, Haijia Medical disclosed its intention to buy back shares, stating that the current trading price does not reflect its intrinsic value [1] - The company executed its first buyback on December 17, purchasing approximately 493,800 shares for about HKD 6.0098 million [1] Group 2: Market Performance and Sentiment - On December 12, Haijia Medical's stock hit a year-low of HKD 11.33, indicating a downward trend away from the 5-day moving average [3] - Following the buyback announcement, the stock price rose by 3.27% on December 16, although it showed signs of selling pressure with a significant increase in trading volume [6][9] - The trading volume on December 16 surged to 11.5494 million shares, a 152.05% increase from the previous day, indicating a shift in market sentiment [6] Group 3: Financial Performance and Valuation - Haijia Medical's mid-year report indicated a decline in revenue from inpatient services by 18.4% year-on-year, while outpatient services saw a decrease of 11.2% [10] - The company reported stable patient visits at 2.2 million, suggesting that demand for its services remains unaffected despite revenue fluctuations [10] - The company's capital expenditure has decreased by 28.5% to RMB 242 million, indicating a shift towards mergers and acquisitions rather than new hospital constructions [11] Group 4: Valuation Comparison - Haijia Medical's price-to-earnings (PE) ratio stands at 15.71, which is below the industry average of 17, suggesting that the company is undervalued compared to its peers [12]